NEW YORK, Sept. 5 — Geneva Bioinformatics, the commercial arm of the Swiss Institute of Bioinformatics (SIB), said on Tuesday it had obtained the rights to exclusively distribute GlycoSuite, Proteome Systems’ database of protein glycosylation.

Glycosylation is a variety of protein modifications important in protein function and diseases such as cancer.

“A significant problem was that information concerning glycosylation was scattered throughout the literature in thousands of scientific publications,” said Proteome Systems CEO Keith Williams in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.